VOL.: 26 (1981) (p. 365)
Vincristine sulphate can induce teratogenic effects in several animal species, and it induced embryolethality at doses nontoxic to the mother. There is no evidence to suggest that this compound is mutagenic.
The available data are insufficient to evaluate the teratogenicity of this drug in humans. No data were available on its mutagenic or chromosomal effects.
Both case reports and epidemiological studies indicate that acute nonlymphocytic leukaemia is produced in patients with Hodgkin's disease treated with combined therapeutic regimens which include vincristine sulphate, alkylating agents and procarbazine hydrochloride, often in conjunction with radiotherapy. No data were available on vincristine sulphate alone.
On the basis of the available data, no conclusion could be drawn as to the carcinogenicity of vincristine sulphate.
For definition of the italicized terms, see Preamble Evaluation.
Subsequent evaluation: Suppl. 7 (1987)
See Also: Toxicological Abbreviations Vincristine Sulphate (IARC Summary & Evaluation, Supplement7, 1987)